JP6550039B2 - Ａｂｃａ１発現の音響化学誘導およびそのための組成物 - Google Patents

Ａｂｃａ１発現の音響化学誘導およびそのための組成物 Download PDF

Info

Publication number
JP6550039B2
JP6550039B2 JP2016502027A JP2016502027A JP6550039B2 JP 6550039 B2 JP6550039 B2 JP 6550039B2 JP 2016502027 A JP2016502027 A JP 2016502027A JP 2016502027 A JP2016502027 A JP 2016502027A JP 6550039 B2 JP6550039 B2 JP 6550039B2
Authority
JP
Japan
Prior art keywords
composition
microspheres
abca1
plasmid
liver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016502027A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016514155A5 (https=
JP2016514155A (ja
Inventor
エリック コールズ
エリック コールズ
マイケル ダビッドソン
マイケル ダビッドソン
Original Assignee
ソノジェン リミテッド ライアビリティ カンパニー
ソノジェン リミテッド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ソノジェン リミテッド ライアビリティ カンパニー, ソノジェン リミテッド ライアビリティ カンパニー filed Critical ソノジェン リミテッド ライアビリティ カンパニー
Publication of JP2016514155A publication Critical patent/JP2016514155A/ja
Publication of JP2016514155A5 publication Critical patent/JP2016514155A5/ja
Application granted granted Critical
Publication of JP6550039B2 publication Critical patent/JP6550039B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasonic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasonic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0092—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin using ultrasonic, sonic or infrasonic vibrations, e.g. phonophoresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Medical Informatics (AREA)
  • Dermatology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Acoustics & Sound (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2016502027A 2013-03-14 2014-03-13 Ａｂｃａ１発現の音響化学誘導およびそのための組成物 Expired - Fee Related JP6550039B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/826,066 US9101745B2 (en) 2013-03-14 2013-03-14 Sonochemical induction of ABCA1 expression and compositions therefor
US13/826,066 2013-03-14
PCT/US2014/026018 WO2014160196A2 (en) 2013-03-14 2014-03-13 Sonochemical induction of abca1 expression and compositions therefor

Publications (3)

Publication Number Publication Date
JP2016514155A JP2016514155A (ja) 2016-05-19
JP2016514155A5 JP2016514155A5 (https=) 2017-04-20
JP6550039B2 true JP6550039B2 (ja) 2019-07-24

Family

ID=51530678

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016502027A Expired - Fee Related JP6550039B2 (ja) 2013-03-14 2014-03-13 Ａｂｃａ１発現の音響化学誘導およびそのための組成物

Country Status (6)

Country Link
US (2) US9101745B2 (https=)
EP (1) EP2970991B1 (https=)
JP (1) JP6550039B2 (https=)
AU (1) AU2014244014B2 (https=)
CA (1) CA2902047A1 (https=)
WO (1) WO2014160196A2 (https=)

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
JPH03297475A (ja) 1990-04-16 1991-12-27 Ken Ishihara 共振音波により薬物の放出を制御する方法
ATE146073T1 (de) 1991-03-22 1996-12-15 Katsuro Tachibana Verstärker zur ultraschalltherapie von erkrankungen sowie diesen enthaltende flüssige arzneimittelzusammensetzungen
CN1056124A (zh) 1991-06-05 1991-11-13 清华大学 高效超声波基因导入方法
BR9405798A (pt) 1993-02-22 1995-12-12 Vivorx Pharmaceuticals Inc Métodos para liberação in vivo de material biológico e composições úteis dos mesmos
ES2152990T3 (es) 1993-09-09 2001-02-16 Schering Ag Principios activos y microparticulas que contienen gases.
US6048903A (en) 1994-05-03 2000-04-11 Robert Toppo Treatment for blood cholesterol with trans-resveratrol
US5558092A (en) 1995-06-06 1996-09-24 Imarx Pharmaceutical Corp. Methods and apparatus for performing diagnostic and therapeutic ultrasound simultaneously
US6139819A (en) 1995-06-07 2000-10-31 Imarx Pharmaceutical Corp. Targeted contrast agents for diagnostic and therapeutic use
US6265387B1 (en) 1995-10-11 2001-07-24 Mirus, Inc. Process of delivering naked DNA into a hepatocyte via bile duct
US20010009904A1 (en) 1997-12-30 2001-07-26 Jon A. Wolff Process of delivering a polynucleotide to a cell via the vascular system
US5849727A (en) 1996-06-28 1998-12-15 Board Of Regents Of The University Of Nebraska Compositions and methods for altering the biodistribution of biological agents
AU732872C (en) 1996-08-15 2002-02-21 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Spatial and temporal control of gene expression using a heat shock protein promoter in combination with local heat
JP2002515887A (ja) 1996-10-19 2002-05-28 クウォドラント、ヘルスケアー、（ユーケー）、リミテッド 診断および治療における中空マイクロカプセルの使用
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6575956B1 (en) 1997-12-31 2003-06-10 Pharmasonics, Inc. Methods and apparatus for uniform transcutaneous therapeutic ultrasound
US6066123A (en) 1998-04-09 2000-05-23 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of bioavailability by use of focused energy delivery to a target tissue
US6135976A (en) 1998-09-25 2000-10-24 Ekos Corporation Method, device and kit for performing gene therapy
WO2000042988A1 (en) 1999-01-21 2000-07-27 University Of Virginia Method of identifying and treating inflamed tissue
SG121853A1 (en) * 1999-06-18 2006-05-26 Cv Therapeutics Inc Compositions and methods for increasing cholesterol efflux and raising hdl using atp binding cassette transporter protein abc1
US6821774B1 (en) 1999-06-18 2004-11-23 Cv Therapeutics, Inc. Compositions and methods for increasing cholesterol efflux and raising HDL using ATP binding cassette transporter ABC1
DE60026313D1 (de) 1999-07-23 2006-04-27 Uutech Ltd Sensibilisierung von roten blutkörperchen gegenüber ultraschall durch einwirkung eines elektrischen feldes
JP2002145784A (ja) * 2000-11-10 2002-05-22 Ryuichi Morishita 生物学的活性薬剤導入組成物およびその使用方法
CA2452471C (en) * 2001-07-10 2010-06-29 Michael N. Davidson Enhancement of transfection of dna into the liver
US7470659B2 (en) 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)

Also Published As

Publication number Publication date
EP2970991A4 (en) 2016-11-30
US20150343098A1 (en) 2015-12-03
WO2014160196A2 (en) 2014-10-02
WO2014160196A9 (en) 2015-01-29
US20140276363A1 (en) 2014-09-18
CA2902047A1 (en) 2014-10-02
AU2014244014A1 (en) 2015-09-17
JP2016514155A (ja) 2016-05-19
US9101745B2 (en) 2015-08-11
US9393328B2 (en) 2016-07-19
EP2970991B1 (en) 2022-04-27
WO2014160196A3 (en) 2014-11-27
AU2014244014B2 (en) 2019-08-01
EP2970991A2 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
Gao et al. Targeted mRNA nanoparticles ameliorate blood–brain barrier disruption postischemic stroke by modulating microglia polarization
JP6392209B2 (ja) 粘液内層を通過する迅速な透過のための脂質ベース薬物キャリア
Yang et al. Stimuli-responsive nanomedicines for the treatment of non-cancer related inflammatory diseases
Kong et al. Cationic solid lipid nanoparticles derived from apolipoprotein-free LDLs for target specific systemic treatment of liver fibrosis
Pradhan et al. Perspectives of lipid-based drug carrier systems for transdermal delivery
Dai et al. Emerging innovations on exosome-based onco-therapeutics
Yamashita et al. A novel bubble liposome and ultrasound-mediated gene transfer to ocular surface: RC-1 cells in vitro and conjunctiva in vivo
JP2001507207A (ja) 化合物を細胞に送達する方法
JP7314270B2 (ja) トランスフェクション方法
US12178981B2 (en) Drug administration method
US9457102B2 (en) Therapeutic muscular dystrophy drug having bubble liposome loaded with morpholino as active ingredient
JP6550039B2 (ja) Ａｂｃａ１発現の音響化学誘導およびそのための組成物
JP4426288B2 (ja) 肝臓へのｄｎａのトランスフェクションの増強
Tang et al. Polysorbate 80-containing ionizable lipid nanoparticles for mRNA delivery
Zhang et al. Targeting mitochondrial copper (II) for epigenetic modulation of macrophage polarization to prevent senile osteoporosis
Mehier-Humbert et al. Influence of polymer adjuvants on the ultrasound-mediated transfection of cells in culture
Chen et al. Photothermal-Boosted Neutrophil-Mediated STING Inhibitor Delivery Platforms for Drug-Resistant Diabetic Wound Infections
Oujagir et al. Therapeutic efficacy of in-vivo IL-12 plasmid delivery using microbubble-assisted ultrasound in a B16F10 mouse melanoma model: A proof of concept
CN118948798A (zh) 一种载PDGF-BB mRNA的纳米复合物及其制备方法与应用
KR20250022641A (ko) 과불화탄소를 함유한 유전자 약물 전달용 지질 나노입자, 및 이의 제조방법
WO2024160819A1 (en) Nanoparticles with antibodies for ocular treatment
Brož Nanotechnologies for Targeted Delivery of
WO2025258656A1 (ja) 肺疾患の治療に用いられるｍｉＲＮＡまたはｍｉＲＮＡ ｍｉｍｉｃ内封脂質ナノ粒子および医薬組成物
US8778875B2 (en) Use of an active biological substance in abnormal cellular and viral membrane physiologies
CN117618383A (zh) 负载ssk1的神经递质衍生纳米载体及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170313

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170313

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180315

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181025

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190419

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190606

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190628

R150 Certificate of patent or registration of utility model

Ref document number: 6550039

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees